Skip to main content
. 2019 Nov 8;22(1):94–102. doi: 10.1093/neuonc/noz164

Fig. 2.

Fig. 2

Biomarker immunohistochemistry analysis for adult recurrent glioblastoma patient treated with ONC201. Left panel shows DRD2 and DRD5 expression in archival tumor sample. Right panel shows pharmacodynamic biomarkers of ONC201 in archival tumor sample (archival) and in tumor sample resected ~24 hours after the second weekly dose of 625 mg ONC201 (on-treatment). Scale bars: 200 µm.